Apellis Pharmaceuticals: Have Some Patience

The market is currently underscoring the FCF potentials of Syfovre and Empaveli. While the firm had initially struggled to roll out Syfovre due to reports of infections, the drug is projected to reach over $1bn in sales per year by A longtime investor with a general interest in healthcare equities. I take a holistic investment approach that considers top-down and bottom-up valuation techniques. I find the more minute details of companies, including their capital structure and debt covenants, play an outsize ...